Loading...
Market
What will be the revenue generated by ORLYNVAH in its first year post-approval by October 25, 2025?
2
Resolution / Starting Odds
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Financial reports from Iterum Therapeutics or industry analysis reports
Story
FDA Approves Iterum's Oral Antibiotic ORLYNVAH for Uncomplicated UTIs in Women on October 25, 2024
Oct 25, 2024, 03:58 PM
The U.S. Food and Drug Administration (FDA) has approved Iterum Therapeutics' oral antibiotic, ORLYNVAH, for the treatment of uncomplicated urinary tract infections (UTIs) in adult women. This announcement was made on Friday, October 25, 2024. The approval is significant as it addresses a common health issue among women, providing a new treatment option. The FDA's decision follows a period of heightened trading activity for Iterum Therapeutics, indicated by a notable increase in volume prior to the announcement. The company's market capitalization remains low, suggesting potential for growth following this approval.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%
More than $300 million • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $200 million • 25%
More than $200 million • 25%
Below $500M • 33%
$500M - $1B • 33%
Above $1B • 34%
Less than $500 million • 33%
$500 million to $1 billion • 33%
More than $1 billion • 33%
Less than $20 million • 25%
$20 million to $25 million • 25%
$25 million to $30 million • 25%
More than $30 million • 25%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%